Younossi Z - Search Results

1

The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials.

Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, Diehl AM, Caldwell S, Shiffman ML, Aguilar Schall R, Jia C, McColgan B, Djedjos CS, McHutchison JG, Subramanian GM, Myers RP, Younossi Z, Muir AJ, Afdhal NH, Bosch J, Goodman Z. Sanyal AJ, et al. Among authors: younossi z. Hepatology. 2019 Dec;70(6):1913-1927. doi: 10.1002/hep.30664. Epub 2019 May 28. Hepatology. 2019. PMID: 30993748

2

Nonalcoholic fatty liver disease: an agenda for clinical research.

Younossi ZM, Diehl AM, Ong JP. Younossi ZM, et al. Hepatology. 2002 Apr;35(4):746-52. doi: 10.1053/jhep.2002.32483. Hepatology. 2002. PMID: 11915019 Review. No abstract available.

3

Non-alcoholic fatty liver disease: an overview.

Mulhall BP, Ong JP, Younossi ZM. Mulhall BP, et al. J Gastroenterol Hepatol. 2002 Nov;17(11):1136-43. doi: 10.1046/j.1440-1746.2002.02881.x. J Gastroenterol Hepatol. 2002. PMID: 12453271 Review.

4

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, Younossi Z, Albrecht J. Poynard T, et al. Among authors: younossi z. Hepatology. 2003 Jul;38(1):75-85. doi: 10.1053/jhep.2003.50267. Hepatology. 2003. PMID: 12829989 Clinical Trial.

5

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study.

Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, Wright T, Younossi Z, Goon BL, Tang KL, Bowers PJ; Proactive Study Group. Afdhal NH, et al. Among authors: younossi z. Gastroenterology. 2004 May;126(5):1302-11. doi: 10.1053/j.gastro.2004.01.027. Gastroenterology. 2004. PMID: 15131791 Clinical Trial.

6

Nonalcoholic fatty liver disease and the epidemic of obesity.

Collantes R, Ong JP, Younossi ZM. Collantes R, et al. Cleve Clin J Med. 2004 Aug;71(8):657-64. doi: 10.3949/ccjm.71.8.657. Cleve Clin J Med. 2004. PMID: 15449761 Free article. Review.

7

Nonalcoholic Steatohepatitis.

Mulhall BP, Younossi ZM. Mulhall BP, et al. Curr Treat Options Gastroenterol. 2004 Dec;7(6):423-430. doi: 10.1007/s11938-004-0001-9. Curr Treat Options Gastroenterol. 2004. PMID: 15527708

8

Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy.

Pockros PJ, Shiffman ML, Schiff ER, Sulkowski MS, Younossi Z, Dieterich DT, Wright TL, Mody SH, Tang KL, Goon BL, Bowers PJ, Leitz G, Afdhal NH; PROACTIVE Study Group. Pockros PJ, et al. Among authors: younossi z. Hepatology. 2004 Dec;40(6):1450-8. doi: 10.1002/hep.20482. Hepatology. 2004. PMID: 15565613 Clinical Trial.

9

Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients.

Ong JP, Elariny H, Collantes R, Younoszai A, Chandhoke V, Reines HD, Goodman Z, Younossi ZM. Ong JP, et al. Among authors: younossi zm. Obes Surg. 2005 Mar;15(3):310-5. doi: 10.1381/0960892053576820. Obes Surg. 2005. PMID: 15826462

10

Morbid obesity, nonalcoholic fatty liver disease, and weight loss surgery.

Srivastava S, Younossi ZM. Srivastava S, et al. Hepatology. 2005 Aug;42(2):490-2. doi: 10.1002/hep.20782. Hepatology. 2005. PMID: 15977205

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

740 results

Search Page